Sökning: id:"swepub:oai:DiVA.org:liu-86381" >
Impact of cytogenet...
Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT
-
- Chevallier, P (författare)
- CHU Hotel Dieu, France
-
- Labopin, M (författare)
- University of Paris 06, France
-
- Milpied, N (författare)
- CHU Bordeaux, France
-
visa fler...
-
- Cornelissen, J J (författare)
- Erasmus MC Daniel den Hoed Cancer Centre, Netherlands
-
- Blaise, D (författare)
- Institute Paoli Calmette, France
-
- Petersen, E (författare)
- University of Medical Centre Utrecht, Netherlands
-
- Sandstedt, A (författare)
- Östergötlands Läns Landsting,Hematologiska kliniken US
-
- Goker, H (författare)
- Hacettepe University, Turkey
-
- Socie, G (författare)
- Hop St Louis, France
-
- Rocha, V (författare)
- Hop St Louis, France
-
- Mohty, M (författare)
- n/a
-
visa färre...
-
(creator_code:org_t)
- 2012-04-16
- 2012
- Engelska.
-
Ingår i: Bone Marrow Transplantation. - : Nature Publishing Group. - 0268-3369 .- 1476-5365. ; 47:11, s. 1442-1447
- Relaterad länk:
-
https://www.nature.c...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- So far the impact of cytogenetics risk on outcome in the context of reduced intensity conditioning (RIC) allo-SCT has been poorly studied. We have identified 378 AML patients in first CR who underwent RIC allo-SCT from an HLA-matched sibling donor between 2000 and 2007 reported to the European Group for Bone and Marrow Transplantation and for whom detailed cytogenetics data were available (good risk: n = 21; intermediate risk: n = 304; and poor risk: n = 53). With a median follow-up of 24 months (range: 1-93), 2-year non-relapse mortality, relapse rate (RR), leukemia-free survival (LFS) and OS were 14%, 31%, 55% and 61%, respectively. Cytogenetics was significantly associated with RR (good risk: 10%; intermediate risk: 28%; and poor risk: 55% at 2 years, Pandlt;0.0001) and LFS (good risk: 64%; intermediate risk: 57%; and poor risk: 38% at 2 years, P = 0.003). In a multivariate analysis, RR and LFS were significantly higher and lower, respectively, in the high-risk cytogenetics group (P = 0.001, P = 0.004) and in patients with a higher WBC at diagnosis (andgt;10 x 10(9)/L) (Pandlt;0.001, P = 0.004). As documented in the setting of myeloablative allo-SCT, patients with poor cytogenetics had increased RR and decreased LFS after RIC allo-SCT, requiring new prospective strategies to improve results in this subgroup.
Nyckelord
- Allo-SCT
- cytogenetics
- RIC
- AML
- CR
- sibling donor
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Chevallier, P
-
Labopin, M
-
Milpied, N
-
Cornelissen, J J
-
Blaise, D
-
Petersen, E
-
visa fler...
-
Sandstedt, A
-
Goker, H
-
Socie, G
-
Rocha, V
-
Mohty, M
-
visa färre...
- Artiklar i publikationen
-
Bone Marrow Tran ...
- Av lärosätet
-
Linköpings universitet